June 26, 2007 -- China Biopharma (Bulletin Board: CBPC) has signed a tentative agreement with Delmont Laboratory that will allow China Biopharma to distribute in China an immunotherapeutic vaccine called Staphage Lystate. The vaccine is indicated for antibiotic-resistant staph infections and is approved for use in the US. Both China and Western countries are seeing many hospital patients infected with an antibiotic-resistant form of staph infection, called methicillin-resistant Staphylococcus aureus (MRSA). At present, there are no drugs available in China to treat the problem. More details...
